The Journal of the American Association of Gynecologic Laparoscopists · 1997
Relationship of endometrial thickness with the menstrual timing of leuprolide acetate administration for preoperative preparation for hysteroscopic surgery.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nathanson H G, Phillips D R, Milim S J, Haselkorn J S, Kapra A
Аннотация
STUDY OBJECTIVES: To assess the relationship of menstrual timing of administration of gonadotropin-releasing hormone (GnRH) agonist on the effectiveness of endometrial thinning and unwanted uterine bleeding.
DESIGN: Prospective observational study.
SETTING: Gynecology department of a community hospital.
PATIENTS: One hundred consecutive women in a private practice, without submucous myomas, scheduled for transcervical endomyometrial resection or ablation.
INTERVENTIONS: A GnRH agonist was administered at an unspecified time of the menstrual cycle. Transcervical hysteroscopic endomyometrial resection or ablation was performed 1 month later.
MEASUREMENTS AND MAIN RESULTS: No significant statistical differences were seen in either the effectiveness of endometrial thinning or the occurrence or severity of unwanted uterine bleeding.
CONCLUSIONS: A GnRH agonist as pretreatment for endomyometrial resection or ablation can be administered at any time during the menstrual cycle with similar efficacy. Timing of surgery can be at the mutual convenience of patient and physician.
DESIGN: Prospective observational study.
SETTING: Gynecology department of a community hospital.
PATIENTS: One hundred consecutive women in a private practice, without submucous myomas, scheduled for transcervical endomyometrial resection or ablation.
INTERVENTIONS: A GnRH agonist was administered at an unspecified time of the menstrual cycle. Transcervical hysteroscopic endomyometrial resection or ablation was performed 1 month later.
MEASUREMENTS AND MAIN RESULTS: No significant statistical differences were seen in either the effectiveness of endometrial thinning or the occurrence or severity of unwanted uterine bleeding.
CONCLUSIONS: A GnRH agonist as pretreatment for endomyometrial resection or ablation can be administered at any time during the menstrual cycle with similar efficacy. Timing of surgery can be at the mutual convenience of patient and physician.